Lilly Diabetes R&D Center Arms Firm For Battle In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
You may also be interested in...
Lilly’s Lechleiter Sees More Opportunities For Emerging Markets
Eli Lilly CEO John Lechleiter talked about the company’s plans for emerging markets at a recent conference in New York.
Icahn Turns Up The Heat On Amylin, Urges Board To Sell
The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.